European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
Department of Pharmaceutical and Pharmacological Sciences, Clinical Pharmacology and Pharmacotherapy, Katholieke Universiteit Leuven, Leuven, Belgium.
Clin Transl Sci. 2021 Jan;14(1):47-53. doi: 10.1111/cts.12863. Epub 2020 Aug 29.
Although collaborations between academic institutions and industry have led to important scientific breakthroughs in the discovery stage of the pharmaceutical research and development process, the role of multistakeholder partnerships in the clinical development of anticancer medicines necessitates further clarification. The benefits associated with such cooperation could be undercut by the conflicting goals and motivations of the actors included. The aim of this review was to identify and characterize past, present, and future stakeholder partnership models in cancer clinical research through the lens of the European Organisation for Research and Treatment of Cancer (EORTC). Based on the analysis of several landmark EORTC trials performed across the span of three decades, four existing models of stakeholder cooperation were delineated and characterized. Additionally, a hypothetical fifth model representing a potential future collaborative framework for cancer clinical research was formulated. These models mainly differ in terms of the nature and responsibilities of the partners included and show that clinical research partnerships in oncology have evolved over time from small-scale academia-industry collaborations to complex interdisciplinary cooperation involving many different stakeholders.
虽然学术界和产业界之间的合作在药物研发过程的发现阶段带来了重要的科学突破，但多方利益相关者伙伴关系在癌症药物临床开发中的作用仍需要进一步明确。相关合作带来的益处可能会被所涉及的参与者的目标和动机冲突所削弱。本综述旨在通过欧洲癌症研究与治疗组织（EORTC）的视角，确定并描述过去、现在和未来癌症临床研究中的利益相关者伙伴关系模式。基于对 EORTC 进行的几项具有里程碑意义的临床试验进行的分析，确定并描述了现有的四种利益相关者合作模式。此外，还构建了一个代表癌症临床研究潜在未来合作框架的假设第五种模式。这些模式主要在参与方的性质和责任方面存在差异，表明肿瘤学领域的临床研究伙伴关系随着时间的推移已经从小规模的学术界-产业界合作发展为涉及许多不同利益相关者的复杂跨学科合作。
